We are in the business of extending life for patients.

About

We are committed to delivering next-generation cancer therapies.

Coherus is focused on developing and commercializing a diversified portfolio of next-generation immuno-oncology therapies that potentially extend patient survival across tumor types. The approval of LOQTORZI (toripalimab-tpzi) and the advancement of multiple clinical stage immuno-oncology candidates targeting the tumor microenvironment underscore our commitment to immuno-oncology while the established infrastructure of our biosimilar business enables us to provide better treatment access and outcomes for patients with life-altering illnesses.

The approval of LOQTORZI and our diversified pipeline of clinical-stage immuno-oncology candidates targeting the tumor microenvironment underscore our commitment to advancing immuno-oncology treatments.

Every member of the Coherus team is dedicated, motivated, and passionate about improving patient care. Our colleagues are experts in immunology, analytical and process sciences, biologic process development, manufacturing and supply chain management, deeply experienced in clinical development and regulatory affairs, and have proven commercial and marketing capabilities.

For more than a decade, the Coherus team has worked alongside each other across multiple disease areas to successfully develop and commercialize our biosimilars product portfolio. We are now focused on advancing novel immuno-oncology treatments with the same commitment to patients and our team’s proven success in development and commercialization.

Taking the lead in bringing the next generation immuno-oncology treatments to patients.